Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation
NCT02564354
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
18
Enrollment
INDUSTRY
Sponsor class
Conditions
Cystic Fibrosis
Interventions
DRUG:
QR-010
Sponsor
ProQR Therapeutics
Collaborators
[object Object]